NICE Methods Review

Page last updated 26th January 2021

In July 2019, NICE confirmed details of its plans to review the case for change to the methods it uses to develop guidance on drugs, medical devices and diagnostics. The timeline for the next stages of the review is as follows:

  • Feb-Mar 2021: 6-week consultation on evidence and consideration for change to processes.
  • June-July 2021: Stakeholder consultation on the draft programme manual.
  • October 2021: Implementation begins.

Further information about the review is available here.

January 2021: NICE’s 6-week public consultation on its review and proposals started in November 2020. We attended a number of consultations and discussions run both by and for Patient Groups. You can read the key points made in our December response to the consultation

October 2019: we supported Genetic Alliance UK’s 'Action for Access' campaign to improve access to potentially life-changing treatments for people affected by rare diseases (including SMA) - read more

September 2019: the APPG on Access to Medicines and Medical Devices ’s summarised the views of a broadly-based group of stakeholders in its recommendations for the NICE Methods Review. SMA UK attended some of the meetings during which evidence was collected. You can read the report here. The report was taken to Government, the NHS and NICE in order to continue dialogue about what should change to support better patient access to innovative therapies.

April 2019: we joined MPs, representatives of charities supporting patients affected by rare conditions, representatives from pharmaceutical companies and others for the launch of MAP Biopharma’s report ‘Access to Orphan Medicines: A Case for Change’.